Pfizer
NYSE: PFE · Health Care · Pharmaceuticals · NEW YORK, NY
Pharmaceutical company with vaccines (Prevnar), oncology (incl. Seagen), cardiovascular (Eliquis, Vyndaqel) and COVID-19 products.
Annual results
Click any number to open the SEC filing it came from.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| EPS — diluted | $3.85 per share | $5.47 per share | $0.37 per share | $1.41 per share | $1.36 per share |
| Cash from operations | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B |
| Free cash flow | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Total assets | $181.5B | $197.2B | $226.5B | $213.4B | $208.2B |
Recent filings
Members see much more
The full PFE file, with an AI analyst on it.
- Quarterly statements, segments and IR data
- Valuation, earnings and insider activity
- A research assistant that cites the filing sentence